Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00458042 · ClinicalTrials.gov registry record · Phase 4
Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction
A Phase 4 study, sponsored by United Therapeutics.
- Terminated
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
NCT00458042 is a Phase 4 study that was terminated before completion, run by United Therapeutics. The registered enrollment target is 10 participants.
The verdict
NCT00458042, a Phase 4 study, was terminated before completion, sponsored by United Therapeutics.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the effects of switching from inhaled Ventavis to intravenous Remodulin in PAH patients who are considered to be failing inhaled Ventavis therapy. This study is intended to provide information on the safe transition from Ventavis to Remodulin as well as the impact intravenous Remodulin may have on overall quality of life and treatment satisfaction compared to Ventavis.
Interventions
- DRUG treprostinil sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2007-03 |
| Est. Completion | 2007-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00458042
The ClinicalTrials.gov registry entry for NCT00458042 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is United Therapeutics, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which treprostinil sodium is the first listed.
NCT00458042 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00458042 about?
NCT00458042 is a clinical study titled "Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction". The purpose of this study is to compare the effects of switching from inhaled Ventavis to intravenous Remodulin in PAH patients who are considered to be failing inhaled Ventavis therapy. This study is intended to provide information on the safe transition from Ventavis to Remodulin as well as the im...
What is the current status of trial NCT00458042?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2007-03. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00458042?
The interventions under investigation include: treprostinil sodium (DRUG).
Who is sponsoring clinical trial NCT00458042?
This trial is sponsored by United Therapeutics, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.